Results 11 to 20 of about 143,588 (347)

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Nature Communications, 2018
Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who respond to poly(ADP-ribose) polymerase inhibitor (PARPi) therapy is of great clinical importance.
O. Kondrashova, M. Topp, K. Nešić, Elizabeth Lieschke, G. Ho, M. Harrell, Giada V. Zapparoli, A. Hadley, Robert Holian, Emma Boehm, V. Heong, E. Sanij, R. Pearson, J. Krais, N. Johnson, O. Mcnally, Sumitra Ananda, K. Alsop, K. Hutt, S. Kaufmann, K. Lin, T. Harding, N. Traficante, G. A. P. D. S. S. J. K. T. N. M. A. R. T. M. P. J. K. Chenevix-Trench Green Webb Gertig Fereday Moore Hu, G. Chenevix-Trench, A. Green, P. Webb, D. Gertig, S. Fereday, S. Moore, J. Hung, K. Harrap, T. Sadkowsky, N. Pandeya, M. Malt, A. Mellon, R. Robertson, T. Vanden Bergh, M. Jones, P. Mackenzie, J. Maidens, K. Nattress, Y. Chiew, A. Stenlake, H. Sullivan, B. Alexander, P. Ashover, S. Brown, T. Corrish, L. Green, L. Jackman, K. ferguson, K. Martin, A. Martyn, B. Ranieri, J. White, V. Jayde, P. Mamers, L. Bowes, L. Galletta, D. Giles, J. Hendley, T. Schmidt, H. Shirley, C. Ball, C. Young, S. Viduka, H. Tran, S. Bilić, L. Glavinas, J. Brooks, R. Stuart-Harris, F. Kirsten, J. Rutovitz, P. Clingan, A. Glasgow, A. Proietto, S. Braye, G. Otton, J. Shannon, T. Bonaventura, J. Stewart, S. Begbie, M. Friedlander, D. Bell, S. Baron-Hay, A. Ferrier, G. Gard, D. Nevell, N. Pavlakis, S. Valmadre, B. Young, C. Camaris, R. Crouch, L. Edwards, N. Hacker, D. Marsden, G. Robertson, P. Beale, J. Beith, J. Carter, C. Dalrymple, R. Houghton, P. Russell, M. Links, J. Grygiel, J. Hill, A. Brand, K. Byth, R. Jaworski, P. Harnett, R. Sharma, G. Wain, B. Ward, D. Papadimos, A. Crandon, M. Cummings, K. Horwood, A. Obermair, L. Perrin, D. Wyld, J. Nicklin, M. Davy, M. Oehler, C. Hall, T. Dodd, T. Healy, K. Pittman, D. Henderson, J. Miller, J. Pierdes, P. Blomfield, D. Challis, R. McIntosh, A. Parker, B. Brown, R. Rome, D. Allen, P. Grant, S. Hyde, R. Laurie, M. Robbie, D. Healy, T. Jobling, T. Manolitsas, J. McNealage, P. Rogers, B. Susil, E. Sumithran, I. Simpson, K. Phillips, D. Rischin, S. Fox, D. Johnson, S. Lade, M. Loughrey, N. O’Callaghan, W. Murray, P. Waring, V. Billson, J. Pyman, D. Neesham, M. Quinn, C. Underhill, R. Bell, L. Ng, R. Blum, V. Ganju, I. Hammond, Y. Leung, A. McCartney, M. Buck, I. Haviv, D. Purdie, D. Whiteman, N. Zeps, A. Defazio, I. McNeish, D. Bowtell, E. Swisher, A. Dobrovic, M. Wakefield, C. Scott   +182 more
semanticscholar   +2 more sources

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

New England Journal of Medicine, 2021
BACKGROUND Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality.
A. Tutt, J. Garber, B. Kaufman, G. Viale, D. Fumagalli, P. Rastogi, R. Gelber, E. de Azambuja, A. Fielding, J. Balmaña, S. Domchek, K. Gelmon, S. Hollingsworth, L. Korde, B. Linderholm, H. Bandos, E. Senkus, J. Suga, Z. Shao, Andrew W. Pippas, Z. Nowecki, T. Huzarski, P. Ganz, P. C. Lucas, N. Baker, S. Loibl, R. McConnell, M. Piccart, R. Schmutzler, G. Steger, J. Costantino, A. Arahmani, N. Wolmark, E. McFadden, V. Karantza, S. Lakhani, G. Yothers, C. Campbell, C. Geyer   +38 more
semanticscholar   +1 more source

A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genes

Medicine, 2022
This study aimed to identify, characterize, and map the important attributes of the top 100 most cited papers on BRCA1 and BRCA2 genes. The scientific literature on BRCA1 and BRCA2 was searched in the Web of Science Core Collection database using the ...
S. Alkhayyat, Muhammad Khan, Tauseef Ahmad, Haroon, Huma Tariq, M. Baig   +5 more
semanticscholar   +1 more source

A role for the p53 tumour suppressor in regulating the balance between homologous recombination and non-homologous end joining [PDF]

Open Biology, 2016
Loss of p53, a transcription factor activated by cellular stress, is a frequent event in cancer. The role of p53 in tumour suppression is largely attributed to cell fate decisions.
Sylvie Moureau, Janna Luessing, Emma Christina Harte, Muriel Voisin, Noel Francis Lowndes   +4 more
doaj   +1 more source

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

Journal of Clinical Oncology, 2022
PURPOSE To provide precise age-specific risk estimates of cancers other than female breast and ovarian cancers associated with pathogenic variants (PVs) in BRCA1 and BRCA2 for effective cancer risk management.
Shuai Li, Valentina Silvestri, Goska Leslie, T. Rebbeck, S. Neuhausen, J. Hopper, H. Nielsen, Andrew J. Lee, Xin Yang, L. McGuffog, M. Parsons, I. Andrulis, N. Arnold, M. Belotti, Å. Borg, B. Buecher, S. Buys, S. Caputo, W. Chung, C. Colas, Sarah V Colonna, J. Cook, M. Daly, M. de la Hoya, Antoine de Pauw, Hélène Delhomelle, J. Eason, C. Engel, D. G. Evans, U. Faust, T. Fehm, F. Fostira, G. Fountzilas, Megan N. Frone, V. García-Barberán, P. Garre, M. Gauthier-Villars, A. Gehrig, G. Glendon, D. Goldgar, L. Golmard, M. Greene, E. Hahnen, U. Hamann, H. Hanson, T. Hassan, J. Hentschel, J. Horváth, L. Izatt, R. Janavicius, Yue Jiao, E. John, B. Karlan, Sung-Won Kim, I. Konstantopoulou, A. Kwong, A. Laugé, Jong Won Lee, F. Lesueur, Noura Mebirouk, A. Meindl, E. Mouret‐Fourme, H. Musgrave, J. Ngeow Yuen Yie, D. Niederacher, Sue-Kyung Park, I. Pedersen, J. Ramser, S. Ramus, Johanna Rantala, M. Rashid, Florian Reichl, J. Ritter, A. Rump, M. Santamariña, C. Saule, Gunnar Schmidt, R. Schmutzler, L. Senter, Sabariah Shariff, C. Singer, M. Southey, D. Stoppa-Lyonnet, C. Sutter, Y. Tan, S. Teo, M. Terry, M. Thomassen, M. Tischkowitz, A. Toland, Diana Torres, Ana Vega, Sebastian A. Wagner, S. Wang-gohrke, B. Wappenschmidt, B. H. Weber, D. Yannoukakos, A. Spurdle, D. Easton, G. Chenevix-Trench, L. Ottini, A. Antoniou   +101 more
semanticscholar   +1 more source

Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants

JAMA Oncology, 2022
Key Points Question Which cancer types and their clinical characteristics are associated with pathogenic variants in BRCA1 and BRCA2 in addition to breast, ovarian, prostate, and pancreatic cancers?
Y. Momozawa, Rumi Sasai, Y. Usui, K. Shiraishi, Y. Iwasaki, Y. Taniyama, M. Parsons, Keijiro Mizukami, Y. Sekine, M. Hirata, Y. Kamatani, Mikiko Endo, Chihiro Inai, Sadaaki Takata, Hidemi Ito, T. Kohno, K. Matsuda, Seigo Nakamura, K. Sugano, Teruhiko Yoshida, H. Nakagawa, K. Matsuo, Y. Murakami, A. Spurdle, M. Kubo   +24 more
semanticscholar   +1 more source

Detection of BRCA1 Pathogenic Variant in a 24-Year-Old Endometrial Cancer Patient: Risks of Several Hereditary Tumor Syndromes Assessed Using Germline Multigene Panel Testing

Case Reports in Oncology, 2022
A 24-year-old woman suspected of Lynch syndrome was found to carry a BRCA1 pathogenic variant, based on germline multigene panel testing (MGPT). The patient was diagnosed with endometrial carcinoma and underwent modified radical hysterectomy, bilateral ...
Xiaofei Wang, Keika Kaneko, Hiromi Arakawa, Eri Habano, Makiko Omi, Eri Nakashima, Hiroshi Kawachi, Akiko Tonooka, Kohei Omatsu, Hidetaka Nomura, Mayu Yunokawa, Hiroyuki Kanao, Shunji Takahashi, Takeshi Nakajima, Arisa Ueki   +14 more
doaj   +1 more source

Co-expression of tumor suppressor p53 (TP53) and cancer testis antigens (CTAs) as the possible indicator of “cancer-free” status [PDF]

World Cancer Research Journal, 2023
Objective: Biomarkers are biological substances that can be measured and objectively evaluated as indicators of concrete processes at different levels.
D. Marjanidze, S. Iordanishvili, C. Sergi, A. Adithya, E. Gubeladze, S. Gogichashvili, V. Deisadze, E. Kldiashvili   +7 more
doaj   +1 more source

Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights

Frontiers in Cell and Developmental Biology, 2023
BRCA1 and BRCA2 play a critical role in a variety of molecular processes related to DNA metabolism, including homologous recombination and mediating the replication stress response. Individuals with mutations in the BRCA1 and BRCA2 (BRCA1/2) genes have a
A. Ragupathi, Manrose Singh, Alexis M. Perez, D. Zhang   +3 more
semanticscholar   +1 more source

Clinicopathologic characteristics of early-onset breast cancer among unselected young Black women. [PDF]

Cancer
Abstract Background Black women are more likely to develop and die from early‐onset breast cancer. Hereditary breast cancer (HBC) is strongly associated with early age of onset. Accordingly, HBC characteristics in young Black women were evaluated. Methods Black women diagnosed with invasive breast cancer at age 50 years or younger between 2005 and 2018
Beasley HK, Shah T, Tinker RJ, Weidner A, Venton L, Hu C, Roberson ML, Lehmann BD, Couch FJ, Reid S, Metcalfe K, Pal T.   +11 more
europepmc   +2 more sources